Table 1:
Clinical characteristics of lupus glomerulonephritis patients, primary glomerulonephritis patients and control group. Results are expressed as number, means ± S.D., percentage and median (range).
| – |
LG Group (n=15) |
PG Group (n=17) |
Control Group (n=32) |
| Mean age (years) |
39.0 ± 12.7 |
43.3 ± 14.8 |
40.4 ± 10.4 |
| Sex, M/F n |
2/13 |
12/5 |
13/19 |
| Months of diagnosis |
80.5 |
43.0* |
NA |
| Diabetes (n, %) |
2 (13.3%) |
2 (11.8%)* |
0 |
| Hypertension (n, %) |
8 (53.2%) |
16 (94.1%)* |
0 |
| Dyslipidemia (n, %) |
2 (13.3%) |
5 (29.4%) |
0 |
| C3 (mg/dl) |
110.3 ± 27.5 |
125.3 ± 32 |
131.4 ± 30.8 |
| C4 (mg/dl) |
23 (14-37) |
34 (22-38.5) |
28 (16-40) |
| CRP (mg/dl) |
1 (0.1-3.4) |
0.6 (0.1-1.2) |
0.9 (0.1-1.8) |
| Albumin (g/dL) |
3.92 ± 0.6 |
4.0 ± 0.6 |
4.5 ± 0.2 |
| 24 h Proteinuria (mg) |
914± 1719 |
1109 ± 1850 |
156 ± 24 § |
| Creatinine clearance (ml/min) |
102.2 ± 30.3 |
99.1 ± 38.8 |
105.3 ± 16.2 |
| Ca (mg/dl) |
9.1 ± 0.5 |
9.4 ± 0.7 |
9.6 ± 0.5 |
| P (mg/dl) |
3.5 ± 0.8 |
3.3 ± 0.7 |
3.2 ± 0.9 |
| PTH (pg/ml) |
36.3 (28-67) |
40.1 (31-43.9) |
30.7 (23-47) |
| Vitamin D therapy (n, %) |
8 (53.3%) |
11 (68.7%) |
0 |
| Steroid therapy (months) |
48 (39-120) |
20 (7-42) |
NA |
|
Total glucocorticoid cumulative dose, (g)
|
9.06± 4.09
|
5.2± 2.3
|
NA
|
| Immunosuppressive therapy (months) |
47 (33-88) |
8 (3-26) |
NA |
|
SLEDAI-2K
|
8.26± 3.99
|
NA
|
NA
|
LG: lupus glomerulonephritis; PG: primary glomerulonephritis; C3: serum complement C3; C4: serum complement C4; CRP: C-reactive protein; PTH: Parathyroid Hormone; Ca: Calcium; P: Phosphorus; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index. NA: Not applicable.
*p<0.05 LG vs PG; §: p<0.001 Control vs LG and PG.